The private sector, short of funding, is finding NIH a useful source of support. As large-scale biomedical research becomes prevalent and as industry's early-stage R&D productivity falters, both parties have an interest in collaborating more than in the past. But in general, NIH isn't set up to manage the transformation of so many promising discoveries into clinically useful products. It's determined to change that situation with the introduction in October of this year of a "roadmap" for collaborations of many kinds. Even before this event, however, NCI, the largest institute within NIH, had undertaken several public-private programs to expedite development of new products. The institute's experiences illustrate some of advantages and pitfalls of public-private initiatives.
By Wendy Diller
National Institutes of Health (NIH) Director Elias Zerhouni, MD's announcement in early October 2003 of a new "roadmap" for...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.
Wales-based group launches with $140m series A.
Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.
Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.
